The advent of small molecule-based targeted therapy has improved the treatment of both
acute and chronic leukemias. Resistance to small molecule inhibitors has emerged as a …

Purpose: FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (FLT3-ITD)
mutations are common in patients with acute myeloid leukemia (AML). These patients …

FLT3-ITD and FLT3-TKD mutations were observed in approximately 20 and 10% of acute
myeloid leukemia (AML) cases, respectively. FLT3 inhibitors such as midostaurin, gilteritinib …

FLT3 mutations are prevalent in AML patients and confer poor prognosis. Crenolanib, a
potent type I pan-FLT3 inhibitor, is effective against both internal tandem duplications and …

The success of the small molecule tyrosine kinase receptor inhibitor (TKI) imatinib mesylate
(Gleevec) in the treatment of chronic myeloid leukemia (CML) constitutes an eminent …

Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive
acute myeloid leukemia (AML) remains a challenge despite the development of novel FLT3 …

Simple Summary Despite the recent approval of some FLT3 inhibitors by drug regulatory
agencies, treatment guidelines for FLT3-mutated AML still require allogeneic transplantation …

Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We
studied pretreatment and relapse bone marrow samples from patients with FLT3-mutated …

Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute
myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Small molecules that …

Abstract Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells
of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target …